Handelsavisen
prelaunch
Companies Healthcare VOXP.WA
VO
VOXP.WA Warsaw Stock Exchange Healthcare Facilities & Services

Voxp.Wa

$97,80
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
P/E
EV / Rev
Div yield
4,78 %
Op margin
22,8 %
ROE
24,1 %
Net margin
16,9 %
Debt / equity
0,45
Beta
52w range
Volume
Day range
Prev close
Open
Next earnings
Ex-dividend
TR 1Y
About

VOXP.WA operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.

Business. VOXP.WA operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.

Classification92 %
SectorHealthcare
Business sectorHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
ActivityPharmaceuticals
Generated · model-assisted
Sell-side consensus
BUY3 analysts
2 buy1 hold0 sell
Avg 12m price target174,70

Analyst recommendations

3 analysts · consensus Buy
Buy2
Hold1
Sell0
12-month price target
174,70
Consensus of sell-side coverage.
Upcoming events
— missing data
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
Buy
3 analysts · indicative
Ownership
not yet wired
Profitability
24,1 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning VOXP.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to VOXP.WA. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    VOXP.WA operates in the healthcare sector, primarily engaged in pharmaceuticals, and generates revenue through the provision of healthcare services and equipment.

    Classification92 %
    SectorHealthcare
    Business sectorHealthcare Services & Equipment
    IndustryHealthcare Facilities & Services
    ActivityPharmaceuticals
    AI synthesis
    GENERATED

    VOXP.WA maintains a debt-to-equity ratio of 0.45, indicating a relatively conservative capital structure, and a current ratio of 1.4, suggesting moderate liquidity. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

    The company's profitability is reflected in a return on equity of 24.1% and a return on assets of 13.94%, both of which are strong indicators of efficient use of equity and assets. These figures suggest that VOXP.WA is performing well in terms of generating returns for its shareholders and utilizing its assets effectively.

    VOXP.WA's financial snapshot does not provide detailed segment or geographic revenue data, making it difficult to assess the company's exposure to specific markets or the concentration of its revenue. However, the company's operations are primarily within the healthcare sector, which is a global industry.

    The company's growth trajectory is not explicitly detailed in the provided data, but the operating cash flow of 116,687,400 PLN and free cash flow of 32,055,900 PLN suggest that it has the capacity to fund operations and potentially invest in growth opportunities. The capital expenditure of -75,821,400 PLN indicates that the company is investing in its operations.

    The risk assessment for VOXP.WA indicates a medium level of liquidity risk and a low level of dilution risk. The company's net cash position being negative after subtracting total debt is a key flag that could impact its liquidity. The dilution risk is low, which is a positive sign for shareholders.

    Recent events related to VOXP.WA are not detailed in the provided data, but the company's financial performance and risk profile suggest that it is a stable player in the healthcare sector. The company's financials and risk assessment indicate that it is in a position to manage its operations and potentially grow.

    Key takeaways
    • VOXP.WA has a strong return on equity and return on assets, indicating efficient use of equity and assets.
    • The company's debt-to-equity ratio is relatively low, suggesting a conservative capital structure.
    • VOXP.WA's liquidity is moderate, with a current ratio of 1.4, but its net cash position is negative after subtracting total debt.
    • The company's growth potential is supported by its operating and free cash flows, although detailed segment and geographic data are not provided.
    • The risk assessment indicates a medium level of liquidity risk and a low level of dilution risk.
    • margin_outlook_rationale: The company's strong return on equity and return on assets suggest that it is efficiently managing its margins.
    • rd_outlook_rationale: The company's capital expenditure indicates investment in operations, which could support future research and development.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $97,80
    Market cap
    Enterprise value
    P/E
    Non-GAAP P/E
    EV / Revenue
    EV / Op income
    EV / OCF
    P / B
    P / Tangible book
    Tangible book
    $408.9M
    Net cash
    -$185.6M
    Current ratio
    1.4
    Debt / equity
    0.5
    ROA
    13.9%
    ROE
    24.1%
    Cash conversion
    118.0%
    CapEx / revenue
    -13.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Next quarternear-term
    Earnings · next quarterconf 45 %
    EPS
    Consensus EPS
    10,94
    Predicted surprise
    +0,00
    Beat probability
    45 %
    Analysts
    3
    Other metrics
    Revenue
    no estimate
    Segment revenue
    no estimate
    Margin
    no estimate
    Segment margin
    no estimate
    as of 2026-05-04 · Earnings Surprise V1
    Period note: consensus is not fiscal-period-aligned at source — read as consensus vs the last reported actual, not a calibrated same-quarter surprise.
    Full fiscal year~1 year ahead
    Full fiscal year · our forecast vs guidance vs consensus
    MetricOur forecastGuidanceConsensus
    EPSno estimateno estimate10,94
    Revenueno estimateno estimate644,3M PLN
    Operating incomeno estimateno estimate151,6M PLN
    Full-year consensus mean (period as reported by source) · consensus in PLN. Company-level full-year forecast and management guidance are not yet modelled at scale — shown as "no estimate", never inferred.
    Probabilistic model output — not investment advice. · generated 2026-08-04

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Consensus distribution

    sell-side coverage
    Recommendation distribution3 analysts
    Strong buy1
    Buy1
    Hold1
    Sell0
    Strong sell0
    12-month price target$174,70 · Median $174,70
    Low $157,20High $192,20
    Operating income · consensus151,6M PLN
    EPS surprise
    −26,0 %
    reported vs consensus · miss
    Revenue surprise
    −17,0 %
    reported vs consensus · miss

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    Low$157,20
    Mean$174,70
    Median$174,70
    High$192,20
    Spot$97,80
    +78.6 %implied to mean12-month sell-side price targets · ▲ spot

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin22,8 %Above P75
    Net Margin16,9 %Above P75
    ROE24,1 %Best in class
    Capex / Rev-13,0 %Below median
    D/E0,45Below median
    Cash Conv1,18Below median

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • VOXP.WA Market data — financials · 2026-05-29
    • Voxel SA Market data — analyst estimates · 2026-05-29

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    1.8Kshares short+529.5% vs prior
    1days to cover
    69.2%short of daily vol
    191fails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    VOXP.WACanonical
    Warsaw Stock Exchange · USD

    Intel & risk

    PredictorBeat prob45 %Surprise+0,00Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: earnings_forecast (90d)
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage